OpenLegislation

Division II.6.6.1.1.5

United Kingdom

Original text. Later amendments are not shown.

If using the benchmark dose (‘BMD’) approach, the BMDL shall be used as the point of departure for derivation of the ADI. In most cases the choice of the critical endpoint is not expected to change when using the BMDL versus the NO(A)EL approach, since the same biological considerations apply.